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Abstract: OBJECTIVE To determine the efficacy of the thrombopoietin receptor agonist romiplostim for
the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma. METHODS
In the PLATUM phase II open-label, multicenter, single-arm trial, patients diagnosed with Common Ter-
minology Criteria for Adverse Events grade 3 or 4 thrombocytopenia during chemoradiotherapy received
weekly subcutaneous romiplostim injections. PLATUM aimed at demonstrating that the percentage of
thrombocytopenic patients treated with romiplostim able to complete 6 cycles of maintenance temozolo-
mide chemotherapy exceeded 10% (0 = 0.10; A = 0.35). Using type I error equal to 0.05% and 95%
power, 31 patients had to be recruited. According to a Fleming 2-step design with a preplanned interim
analysis after recruitment of 20 patients (step 1), the trial was terminated early for success. RESULTS
Twenty patients were enrolled in step 1. Median age was 61 years (range 33-73). Twelve patients received
6 temozolomide cycles, corresponding to a success rate of 60% (95% confidence interval 36%-81%). Four
patients discontinued temozolomide because they did not respond to romiplostim, 2 for progression, and 2
for adverse events unrelated to romiplostim. CONCLUSION The thrombopoietin receptor agonist romi-
plostim improves exposure to chemotherapy in patients with glioblastoma experiencing temozolomide-
induced thrombocytopenia. CLINICALTRIALSGOV IDENTIFIER NCT02227576. CLASSIFICATION
OF EVIDENCE This study provides Class IV evidence that for patients with glioblastoma and throm-
bocytopenia, romiplostim is effective for the secondary prophylaxis of temozolomide-induced thrombocy-
topenia.
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Objective: To determine the efficacy of the thrombopoetin receptor agonist, romiplostim, for 67 
the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.  68 
Methods: In the PLATUM phase II open-label, multicenter single arm trial, patients diagnosed 69 
with CTCAE grade 3 or 4 thrombocytopenia during chemoradiotherapy received weekly 70 
subcutaneous romiplostim injections. PLATUM aimed at demonstrating that the percentage 71 
of thrombocytopenic patients treated with romiplostim able to complete 6 cycles of 72 
maintenance temozolomide chemotherapy exceeded 10% (p0=0.10; pA=0.35). Using type I 73 
error equal to 0.05 and 95% power, 31 patients had to be recruited. According to a Fleming's 74 
two step design with a preplanned interim analysis after recruitment of 20 patients (step 1), 75 
the trial was terminated early for success. 76 
Results: Twenty patients were enrolled in step 1. Median age was 61 years (range: 33-73). 77 
Twelve patients received six temozolomide cycles, corresponding to a success rate of 60% 78 
(95% confidence interval 36-81%). Four patients discontinued temozolomide because they 79 
did not respond to romiplostim, two for progression, and two for adverse events unrelated to 80 
romiplostim. 81 
Conclusion: The thrombopoetin receptor agonist romiplostim improves exposure to 82 
chemotherapy in glioblastoma patients experiencing temozolomide-induced 83 
thrombocytopenia. 84 
Clinicaltrials.gov identifier: NCT02227576 85 
Classification of Evidence: This study provides class IV evidence that for patients with 86 
glioblastoma and thrombocytopenia, romiplostim is effective for the secondary prophylaxis of 87 








Standard of care for newly diagnosed glioblastoma includes surgery followed by radiotherapy 95 
and concomitant temozolomide and 6 maintenance temozolomide cycles1. 96 
Thrombocytopenia represents the main toxicity of this regimen: the frequency of Common 97 
Terminology Criteria for Adverse Events (CTCAE) grade 3 (25,000-49,000/µl) and 4 98 
(<25,000/ µl) thrombocytopenia in phase III clinical trials varied from 6% to 19.4%2-6. 99 
Consequences of thrombocytopenia include hemorrhage, with increased risk in patients 100 
treated with corticosteroids7. Moreover, thrombocytopenia necessitates dose reductions, 101 
delays of further courses, or discontinuation of chemotherapy which may compromise 102 
survival8. The only option to treat thrombocytopenia is platelet transfusions which ameliorates 103 
thrombocytopenia transiently and at high cost, but without allowing to continue 104 
chemotherapy. Romiplostim (AMG 531, Nplate®) is a thrombopoietin mimetic agent with a 105 
similar mechanism of action as thrombopoietin. The PLATUM study aimed at demonstrating 106 
that romiplostim allows adequate exposure to chemotherapy in glioblastoma patients 107 





PLATUM was a phase II open label, multicenter single arm trial (Figure 1). The primary 113 
objective was to determine the proportion of newly diagnosed glioblastoma patients with 114 
CTCAE grade 3 thrombocytopenia induced by temozolomide up to the fifth maintenance 115 
temozolomide cycle who were able to receive 6 cycles when treated with romiplostim, 116 
providing class IV evidence for efficacy of romiplostim for the management of temozolomide-117 
induced thrombocytopenia. Secondary endpoints included incidence of serious adverse 118 
events, number of postponed temozolomide cycles, duration of delays, number of patients 119 
 6 
with recurrent CTCAE grade 3/4 thrombocytopenia, number of patients receiving platelet 120 
transfusions, and survival. 121 
Inclusion criteria included histologically confirmed newly diagnosed glioblastoma, age>18 122 
years, ECOG performance status 0-2, intent to be treated with standard first-line concomitant 123 
and maintenance temozolomide chemotherapy with radiotherapy over a course of 6 weeks2, 124 
and development of CTCAE grade 3/4 thrombocytopenia. Patients could be enrolled not 125 
earlier than one week after the end of radiotherapy to exclude potential interactions of 126 
romiplostim with radiotherapy. Further eligibility criteria included platelet counts > 100,000/µl, 127 
hemoglobin levels >9.5 g/dl, absolute neutrophil counts >1,000/µl, and absence of 128 
coagulopathy or hematological disease including thrombocytopenia before initiation of 129 
concomitant temozolomide. 130 
 131 
Standard protocol approvals, registrations and patient consents 132 
The study protocol and informed consent form were approved by the French ethics 133 
committee (CPP13/70). All participants provided written informed consent. The trial was 134 
registered on Clinicaltrials.gov (NCT02227576). 135 
 136 
Sample size determination 137 
The primary analysis was conducted to provide class IV evidence that romiplostim allows to 138 
administer 6 maintenance temozolomide cycles after an episode of grade 3/4 139 
thrombocytopenia. According to Gerber and colleagues9, 90% of patients who experience 140 
CTCAE grade 3/4 thrombocytopenia stop temozolomide chemotherapy before completing 6 141 
cycles. PLATUM aimed at demonstrating that the percentage of patients treated with 142 
romiplostim and able to complete chemotherapy was significantly higher than 10% (p0=0.10; 143 
pA=0.35). Using type I error equal to 0.05 and 95% power, 31 evaluable patients had to be 144 
recruited. A Fleming's two-step design was chosen, with 20 subjects included in step 1 145 
(a0=2; b0=6) and eleven subjects in step 2. An interim analysis was planned after 146 
recruitment of 20 evaluable patients in step 1. Three scenarios were pre-defined: (1) success 147 
 7 
rate defined as patients receiving the six planned maintenance temozolomide cycles < 2: 148 
termination for futility (p<P0), (2) success rate > 6 patients: termination for success (p>P0), 149 





Patient characteristics  155 
Twenty patients were enrolled in step 1 between July 2014 and December 2016. 156 
Concomitant temozolomide had been interrupted in 17 patients because of 157 
thrombocytopenia, but no dose reductions were reported. Ten patients presented with 158 
CTCAE grade 3/4 thrombocytopenia during concomitant temozolomide chemoradiotherapy 159 
(median 33 days; range 28-124) (Table 1). Enrolment could not start earlier than one week 160 
after completion of radiotherapy, accordingly, these 10 patients, plus six patients who 161 
developed grade 3/4 thrombocytopenia shortly after completion of radiotherapy, were 162 
enrolled prior to the start of maintenance temozolomide (period I). Four patients were 163 
enrolled thereafter (period II). 164 
 165 
Romiplostim exposure 166 
Romiplostim was administered weekly without interruption from enrollment to completion of 167 
temozolomide for a maximum of 6 cycles in 7 of 12 patients who completed 6 cycles of 168 
maintenance temozolomide. A median of 22 romiplostim injections was administered (range 169 
1-45). The median cumulative dose of romiplostim was 14,000 µg (range 750-41,250 µg). 170 
The median dose per injection was 923 µg (range 446-984 µg). Three patients interrupted 171 
romiplostim, for a median delay of 29 days (range 14-36 days) due to platelet counts 172 
>400,000/µl. No interruption of romiplostim was observed for toxicity except for one patient 173 




Two patients went off study because of adverse events (Table 2). One patient presented with 177 
lower limb ischemia after 3 injections of romiplostim, however, ischemia had probably been 178 
preexisting. The other patient had renal insufficiency secondary to dehydration complicated 179 
by aspiration pneumonia not felt to be related to romiplostim. 180 
 181 
Efficacy outcomes 182 
Twelve of 20 patients received the 6 planned temozolomide maintenance cycles, 183 
corresponding to a success rate of 60% (95% confidence interval, CI, 36.05-80.88%). 184 
Accordingly, PLATUM was terminated for success. Of 16 patients enrolled in period I, 5 185 
patients never started maintenance temozolomide: three for inefficacy of romiplostim and two 186 
for tumor progression; nine patients completed 6 cycles of temozolomide. Of 4 patients 187 
enrolled in period II, one never restarted temozolomide for an adverse event unrelated to 188 
romiplostim, the other 3 patients completed 6 cycles of maintenance temozolomide. 189 
Altogether, romiplostim was stopped for non-efficacy in 4 patients, and tumor progression 190 
and adverse events not related to romiplostim in two patients each. Recurrent CTCAE grade 191 
3/4 thrombocytopenias were observed in 17 patients. A total of 33 platelet transfusions were 192 
administered, to a total of 9 patients (median of 2 transfusions per patient, range 1-12 193 
transfusions). 194 
Among the overall 12 patients who received 6 cycles of maintenance temozolomide, the 195 
median length of a temozolomide cycle while treated with romiplostim was 39 days (range 196 
27-80). Temozolomide was postponed for a median of 8.5 days per cycle (range 0-52 days) 197 
after romiplostim initiation for these patients. Maintenance cycle delays were mainly related 198 
to thrombocytopenia (35 cycles). Other causes included neutropenia (2 cycles), 199 
thrombocytopenia plus neutropenia, thrombocytopenia plus general status alteration, and 200 
acute gastroenteritis (1 cycle each). A dose reduction of temozolomide was instituted in 10 201 
patients. 202 
 9 
At the time of the final analysis, 13 patients have experienced recurrence and 15 patients 203 
have died. PFS at 6 months was 85%. Actuarial median PFS after surgery was 14.4 months 204 
(95% CI 12.9-24.8 months). Actuarial median overall survival was 22.9 months (95% CI 10.0-205 





Relative to a historical benchmark9, romiplostim allowed to increase the percentage of 211 
patients with temozolomide-induced grade 3/4 thrombocytopenia that were able to complete 212 
6 cycles of maintenance temozolomide chemotherapy, from 10% to 60%. No severe adverse 213 
events attributed to romiplostim were reported. One pulmonary embolism was observed, not 214 
exceeding expectations, and no major bleeding was reported. There was no evidence for a 215 
detrimental effect of romiplostim for PFS or overall survival.  216 
PLATUM was a small trial with inherent limitations. We cannot exclude that coexposure to 217 
drugs other than temozolomide, e.g., trimethoprim sulfamethoxazole or anti-epileptic drugs, 218 
contributed to thrombocytopenia. A randomized trial to confirm that romiplostim helps 219 
reducing platelet transfusions and bleeding complications, and, more importantly, improves 220 
outcome in patients presenting with chemotherapy-induced thrombocytopenia by allowing to 221 
complete chemotherapy is planned by the European Organization for Research and 222 
Treatment of Cancer. Such a trial should be conducted in a molecularly enriched 223 
chemosensitive patient population, e.g., those with MGMT promoter methylation who are 224 




This study was supported by a grant from Amgen (Thousand Oaks, California). Romiplostim 229 




Table 1: Patient characteristics at baseline and during the concomitant and 233 
maintenance treatment phases 234 
 235 
  
Baseline characteristics  
  










60.5 years (33-72) 
  











1 (range 0-3) 
  


































Steroids within 14 days of registration, n patients (%) 16 (80%) 
  
Anti-epileptic medication within 14 days of registration, n patients (%) 
levetiracetam 
levetiracetam + clozabam 
levetiracetam + perampanel 
pregabalin 










Median platelet count (/µl )(range) at first grade 3/4 thrombocytopenia 28,000 (6,000-48,000) 
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Time (median/range) from initiation of temozolomide chemoradiotherapy to first 
grade 3/4 thrombocytopenia 
42 days (28-169) 
  
Median lowest platelet count prior to registration (/µl )(range) 24,500 (6,000-
59,000)***** 
  
Median time from initiation of temozolomide chemoradiotherapy to lowest 
platelet count prior to registration 
54.5 days (28-327) 
  
Median platelet count at inclusion (/µl )(range) 53,500 (25,000-242,000) 
  
Concomitant temozolomide and radiotherapy treatment phase  
  















Dose of radiotherapy, n patients 
58 Gy (in fractions of 2 Gy) 
60 Gy (in fractions of 2 Gy) 






Interruption of radiotherapy***, n patients 3 
  
Median duration of concomitant temozolomide with radiotherapy 34 days (range 24-44) 
  
Interruption of concomitant temozolomide with radiotherapy****, n patients 17 
  









Time interval (median/range) between initiation of temozolomide 
chemoradiotherapy and grade 3/4 thrombocytopenia 
33 days (28-124) 
  
Maintenance temozolomide treatment phase  
  
Median time between end of radiotherapy and temozolomide initiation for 11 of 
16 patients enrolled in period I that started maintenance temozolomide 
58 days  
(range 27-180 days) 
  
Median time between initiation of chemoradiotherapy and temozolomide 
initiation for 11 of 16 patients enrolled in period I that started maintenance 
temozolomide 
102 days  
(range 78-222 days) 
  







Time interval between initiation of maintenance temozolomide and grade 3/4 
thrombocytopenia for 11 of 16 patients enrolled in period I that started 
maintenance temozolomide 
40 days (16-282 days) 
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Median highest dose of temozolomide after romiplostim initiation among 
patients who completed 6 cycles of temozolomide 
150 mg/m2  
(range 125-200 mg/m2) 
  
Median dose of temozolomide during maintenance treatment among patients 
who completed 6 cycles of temozolomide 
150 mg/m2  
(115-187.5 mg/m2) 
  
Median dose of temozolomide used for the 6th temozolomide cycle among 
patients who completed 6 cycles of temozolomide 
125 mg/m2  
(110-200 mg/m2) 
  
Outcomes with romiplostim  
  
Patients enrolled in period I (n=16) 
Started maintenance temozolomide 
Completed six cycles of temozolomide 
Stopped romiplostim for: 
- inefficacy 
- progressive disease 









Patients enrolled in period II (n=4) 
Completed six cycles of temozolomide 
Stopped romiplostim for: 
- inefficacy 
- progressive disease 









*A bone marrow biopsy was to be performed for patients aged 60 years or older in order to 238 
detect a potential fibrosis which would predict unresponsiveness to romiplostim. Ten of the 239 
13 patients aged 60 years or more had a bone marrow biopsy which showed no bone 240 
marrow fibrosis in any patient. 241 
**resection between 90 and 100% 242 
***Radiotherapy was interrupted for 5, 10 and 44 days in 3 patients because of 243 
thrombocytopenia at 26,000/µl,16,800/µl (twice in one patient), and 6,000/µl and 30,000/µl, 244 
respectively 245 
****Concomitant temozolomide was interrupted during radiotherapy in 17 patients, all for 246 
thrombocytopenia including 10 patients with grade 3/4 thrombocytopenia, for a median 247 
length of interruption of 10 days (range 2-61 days). The dose of temozolomide was not 248 
reduced during concomitant temozolomide with radiotherapy for patients without 249 
temozolomide interruption. 250 
*****One patient was enrolled with a lowest platelet count of 59,000/µl (protocol violation). 251 
This patient was enrolled in period I and received 33 injections of romiplostim. Six cycles of 252 
temozolomide maintenance cycles were administered, 3 of which were delayed (median 253 
duration of delayed: 53 days). 254 
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Table 2: Summary of adverse events from the first administration of romiplostim up to 30 days after the last administration of 
romiplostim 
 
Events (number and %, all grades) CTCAE grade 1 CTCAE grade 2 CTCAE grade 3 CTCAE grade 4   CTCAE grade 5 
Blood and lymphatic disorders: 33 (55%) 
Anemia: 10 (30%) 
Leukopenia: 4 (15%) 
Neutropenia: 6 (25%) 
Lymphopenia: 7 (20%) 
Thrombocytopenia: 3 (15%) 
Aplasia: 3 (15%) 
2 (not related) (10%) 





5 (not related) (20%) 
2 (not related) (10%) 
3 (not related) (15%) 
4 (not related) (15%) 
NA 
1 (not related) (5%) 
3 (not related) (15%) 
1 (not related) (5%) 
2 (not related) (10%) 
3 (not related) (10%) 
1 (not related) (5%) 
1 (not related) (5%) 
0 
0 
1 (not related) (5%) 
0 
2 (not related) (10%)  
1 (not related) (5%) 
  0 
  0 
  0 
  0 
  0 
  0 
Vascular disorders: 7 (20%) 
Hematoma: 3 (15%) 
Arterial hypertension: 2 (10%) 
Lower limb ischemia: 1 (5%) 
Pulmonary embolism: 1 (5%)  
0 
2 (not related) (10%) 
0 
0 







1 (not related) (5%) 
0 
0 
1 (not related) (5%) 
0 
  0 
  0 
  0 
  0 
General disorders and administration site conditions: 32 (60%).  
Injection site hematoma: 2 (10%) 
Fatigue: 26 (60%) 
Face edema: 1 (5%) 
General physical health deterioration: 2 
(10%) 
Generalized edema: 1 (5%) 
Falls: 2 (10%) 
2 (related) (10%) 
15 (12 not related; 3 related) (45%; 15%) 
1 (not related) (5%) 
0 
0 
1 (not related) (5%) 
0 
8 (7 not related; 1 related) (20%; 5%) 
0 
0 
1 (not related) (5%) 
0 
0 
3 (not related) (15%) 
0 
1 (not related) (5%) 
0 




1 (not related) (5%) 
0 
0 
  0 
  0 
  0 
  0 
  0 
  0 
Ear and labyrinth disorders: 2 (10%) 
Vertigo: 2 (10%) 2 (not related) (10%) 0 0 0   0 
Infection and infestations: 10 (50%) 
Pneumopathy: 5 (25%)  
Gastroenteritis: 1 (5%) 
Urinary tract infection: 1 (5%) 
Oral fungal infection: 1 (5%) 
Sinusitis: 1 (5%) 
Cough: 1 (5%) 
0 
1 (not related) (5%) 
1 (not related) (5%) 
0 
0 
1 (not related) (5%) 
2 (not related) (10%) 
0 
0 
1 (not related) (5%) 
1 (not related) (5%) 
0 












  1 (not related) (5%) 
  0 
  0 
  0 
  0 
  0 
Gastro-intestinal disorders: 30 (55%) 
Nausea: 10 (25%) 
Vomiting: 5 (20%) 
Constipation: 6 (30%) 
Diarrhea: 3 (10%) 
Melena: 1 (5%) 
Abdominal pain: 3 (15%) 
Increased gamma glutamyl transferase : 2 
(5%) 
6 (not related) (15%) 
2 (not related) (10%) 
6 (not related) (30%) 




4 (not related) (20%) 
3 (not related) (10%) 
0 
0 
1 (not related) (5%) 
3 (1 not related; 2 related) (5%; 5%) 















  0 
  0 
  0 
  0 
  0 
  0 
  0 
Metabolism and nutrition disorders: 7 (20%) 
Anorexia: 5 (10%) 
Vitamin D deficiency: 1 (5%) 
3 (not related) (10%) 
0 
1 (not related) (5%) 
1 (not related) (5%) 




  0 
  0 
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Polydipsia: 1 (5%) 0 1 (not related) (5%) 0 0   0 
Renal and urinary disorders: 1 (5%) 
Acute renal failure: 1 (5%) 0 0 0 0   1 (not related) 
Musculoskeletal and connective tissue disorders: 6 (30%) 
Arthralgia: 4 (20%) 
Myopathy: 1 (5%) 
Myalgia: 1 (5%) 
3 (not related) (15%) 
0 
1 (related) (5%) 









  0 
  0 
  0 
Nervous system disorders: 14 (50%) 
Intracranial hypertension: 3 (15%) 
Headache: 8 (30%) 
Seizure: 2 (10%) 
Tremor: 1 (5%) 
0 
2 (not related) (10%) 
0 
1 (not related) (5%) 
1 (not related) (5%) 
5 (not related) (20%) 
1 (not related) (5%) 
0 
0 
1 (not related) (5%) 
1 (not related) (5%) 
0 




  1 (not related)* (5%) 
  0 
  0 
  0 
Psychiatric disorders: 9 (40%) 
Anxiety: 4 (20%) 
Depression: 2 (10%) 
Insomnia: 2 (10%) 
Hallucinations: 1 (5%) 
0 
1 (not related) (5%) 
2 (not related) (10%) 
0 
3 (not related) (15%) 
1 (not related) (5%) 
0 
1 (not related) (5%) 








  0 
  0 
  0 
  0 
Skin and subcutaneaous tissue disorders: 5 (20%) 
Dry skin: 1 (5%) 
Dermatitis allergicica: 1 (5%) 
Pruritus: 2 (5%) 
Purpura: 1 (5%) 





1 (not related) (5%) 
2 (related) (5%) 









  0 
  0 
  0 
  0 
Eye disorders: 1 (5%) 
Cataract: 1 (5%) 0 0 1 (not related) (5%) 0   0 
 
 
Adverse events were classified by system organ class and graded according to CTCAE v4.0. 
Hundred-seventy adverse events were documented in all patients (100%), 38 grade 3 to 5 adverse events were documented in 12 patients 





Figure 1. Design of the PLATUM trial1 
 
 
*RT, radiotherapy; TMZ, temozolomide. 
 
1 Patients were to receive weekly subcutaneous injections of romiplostim at a starting dose of 
750 µg. Dose adjustments were based on weekly platelets counts. Four dose levels were 
defined: 250 µg, 500 µg, 750 µg and 1,000 µg. If platelet counts were higher than 400,000/µl, 
romiplostim was withheld and re-initiated at one dose level below when platelet counts 
dropped below 200,000/µl. In case of non-response, defined by platelet counts below 
100,000/µl despite romiplostim injections, a maximum of 6 consecutive weekly injections 
were allowed. The administration of temozolomide was not permitted if platelet counts were 
below 100,000/µl. Patients were seen weekly for clinical and safety evaluation and 
administration of romiplostim. Brain MRI was performed every 3 months and tumor status 
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